Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
์ข
๋ชฉ ์ฝ๋ APUS
ํ์ฌ ์ด๋ฆApimeds Pharmaceuticals US Inc
์์ฅ์ผMay 09, 2025
CEOMr. Erik C. Emerson
์ง์ ์2
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃMay 09
์ฃผ์100 Matawan Road
๋์MATAWAN
์ฆ๊ถ ๊ฑฐ๋์NYSE American Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ07747
์ ํ18482015010
์น์ฌ์ดํธhttps://www.apimedsus.com/
์ข
๋ชฉ ์ฝ๋ APUS
์์ฅ์ผMay 09, 2025
CEOMr. Erik C. Emerson
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์